The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas
作者： W. Vogel , R. Kath , H. Kosmehl , E. Olschowsky , K. H�ffken
DOI: 10.1007/BF01226269
关键词: Adenocarcinoma 、 Colorectal cancer 、 Pathology 、 Gene expression 、 Gene product 、 Alkaline phosphatase 、 Rectum 、 Neu oncogene 、 Hematology 、 Cancer research 、 Internal medicine 、 Medicine
摘要: We report on our experience investigating the serum levels of soluble domain p185 and theneu protein expression in corresponding tumour tissue patients with advanced gastrointestinal carcinomas. The study included 32 who were treated palliative chemotherapy. investigated by immunosorbent assay techniques. used alkaline phosphatase/anti-(alkaline phosphatase) method for immunohistochemically. Increased serumneu found 8 22 (36%) colorectal carcinomas 2 abdominal adenocarcinoma unknown primary. All other cancers serum-neu-protein-negative. serum-neu-protein-positive showed also an elevatedneu expression. extent corresponded to clinical course marker CA 19–9. may be useful monitoring carcinomas, particularly cases immunohistochemicalneu-protein-positive primary tumours.
springer.com
sci-hub.se 参考文章(24)
T Lam, K L Trimpe, P J Marks, W P Carney, S J McKenzie, J Morgan, D L Panicali, Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene. ,vol. 4, pp. 543- 548 ,(1989)
J R Zabrecky, T Lam, S J McKenzie, W Carney, The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. Journal of Biological Chemistry. ,vol. 266, pp. 1716- 1720 ,(1991) , 10.1016/S0021-9258(18)52354-1
Ituo Miyazaki, Shigekazu Ohoyama, Itasu Ninomiya, Akio Yamaguchi, Motohiro Tanaka, Yutaka Yonemura, Takuma Sasaki, Yoshio Endou, Sachio Fushida, Hironobu Kimura, Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Research. ,vol. 51, pp. 1034- 1038 ,(1991)
Arnulf H. Hoelscher, Elfriede Bollschweiler, Nadia Harbec, Karen Becker, J. Ruediger Siewert, Tsutomu Nakamura, Hjalmar Nekarda, Prognostic value of DNA ploidy and cerbB‐2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus Cancer. ,vol. 73, pp. 1785- 1794 ,(1994) , 10.1002/1097-0142(19940401)73:7<1785::AID-CNCR2820730703>3.0.CO;2-0
Alan L. Schechter, David F. Stern, Lalitha Vaidyanathan, Stuart J. Decker, Jeffrey A. Drebin, Mark I. Greene, Robert A. Weinberg, The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. ,vol. 312, pp. 513- 516 ,(1984) , 10.1038/312513A0
Amanda McCann, Peter A. Dervan, P. A. Johnston, Desmond N. Carney, William J. Gullick, c-erbB-2 oncoprotein expression in primary human tumors Cancer. ,vol. 65, pp. 88- 92 ,(1990) , 10.1002/1097-0142(19900101)65:1<88::AID-CNCR2820650119>3.0.CO;2-Z
A.M. Kluftinger, B.W. Robinson, N.F. Quenville, R.J. Finley, N.L. Davis, Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surgical Oncology-oxford. ,vol. 1, pp. 97- 105 ,(1992) , 10.1016/0960-7404(92)90062-P
A H Arnaout, P M Dawson, S Soomro, P Taylor, N A Theodorou, M Feldmann, B M Fendly, H M Shepard, S Shousha, HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. Journal of Clinical Pathology. ,vol. 45, pp. 726- 727 ,(1992) , 10.1136/JCP.45.8.726
J. Jaehne, C. Urmacher, H. T. Thaler, H. Friedlander-Klar, C. Cordon-Cardo, H. J. Meyer, Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. Journal of Cancer Research and Clinical Oncology. ,vol. 118, pp. 474- 479 ,(1992) , 10.1007/BF01629433
Masahiro Tateishi, Teruyoshi Ishida, Tetsuya Mitsudomi, Satoshi Kaneko, Keizo Sugimachi, Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. European Journal of Cancer and Clinical Oncology. ,vol. 27, pp. 1372- 1375 ,(1991) , 10.1016/0277-5379(91)90012-3